Clinical Trial Update: A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated dabrafenib in combination with trametinib in Chinese patients with BRAF V600E-mutant metastatic non-small cell lung cancer. Results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2025-11-04